Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beperminogene perplasmid - AnGes

Drug Profile

Beperminogene perplasmid - AnGes

Alternative Names: AMG 0001 01; AMG-0001; Collategene; Hepatocyte growth factor gene therapy - AnGes; HGF Plasmid-AnGes

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnGes MG
  • Developer AnGes; Er-Kim Ilac; Kamada
  • Class Antiparkinsonians; Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Gene transference; Hepatocyte growth factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Ischaemic heart disorders; Lymphoedema; Parkinson's disease

Highest Development Phases

  • Marketed Chronic limb-threatening ischemia
  • Phase II Arteriosclerosis obliterans
  • Phase I/II Lymphoedema
  • No development reported Ischaemic heart disorders; Parkinson's disease

Most Recent Events

  • 31 May 2023 Anges intends to launch beperminogene perplasmid in the US, Europe and Israel
  • 31 May 2023 AnGes files MAA for full approval for treatment of patients with chronic arterial occlusionin in Japan
  • 03 Mar 2023 AnGes completes enrolment in its phase II trial for Arteriosclerosis obliterans in USA (NCT04267640)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top